Nanyang Biologics Clears SEC Hurdle for $1.5 Billion Nasdaq Listing

The9 Limited, which holds an equity stake in the firm through its Gamenow.net subsidiary, expects to retain a 15% to 16% interest in the combined entity once the transaction closes. The listing remains contingent upon final approval from Nasdaq and the outcome of an extraordinary general meeting of the involved SPAC, scheduled for August 19, 2026.

NYB operates as an AI-first drug discovery laboratory utilizing a proprietary library of over one million natural compounds. Its core technology, the DTIGN neural network, predicts compound binding to disease targets, feeding into the company's Vecura AI platform. To scale these operations, NYB has cultivated a network of high-profile technical partners, including NVIDIA, Hewlett Packard Enterprise, and Equinix, alongside participation in the Johnson & Johnson Innovation JLABS program.